MEDSIR-LED CLINICAL TRIALS UNITE SCIENTIFIC EXCELLENCE, PATIENT FOCUS AND STRATEGIC THINKING. MEDSIR MANAGEMENT MODEL ENSURES SPEED, RELIABILITY AND THE STREAMLINING OF CLINICAL DEVELOPMENT PLANS.
SMART STUDY DESIGNS FOR STRATEGIC CLINICAL TRIALS
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
ABSTRACT (Posters, presentations, etc.)
YEAR
CONGRESS/
JOURNAL
PROJECT
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).
ESMO
2022
PECATI
Abemaciclib with endocrine therapy ± paclitaxel in aggressive ER+/HER2- advanced breast cancer
ESMO
2022
COPÉRNICO
Tocilizumab with pembrolizumab for treatment of COVID-19 pneumonia in patients unresponsive to standard care
International Journal of Infectious Disease
2022
EXACAAPE
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial
European Journal of Cancer
2022
DEBBRAH
Trastuzumab deruxtecan in HER2+ advance breast cancer with brain mets and/or leptomeningeal carcinomatosis
Neuro-Oncology Journal
2022
Other MEDSIR related articles
